Ashoo Gupta
Known title: VP, Finance and ControllerCIK: 0002091461
Associated companies
Transaction History
| FDMT | ▲ Buy | Option Exercise | 865 | — | 3/20/2026 | View on chart |
| FDMT | ▼ Sell | Open Market | 310 | $3K | 3/20/2026 | View on chart |
| FDMT | ▲ Buy | Option Exercise | 221 | — | 3/20/2026 | View on chart |
| FDMT | ▼ Sell | Open Market | 80 | $689 | 3/20/2026 | View on chart |
| FDMT | ▲ Buy | Option Exercise | 866 | — | 12/20/2025 | View on chart |
| FDMT | ▼ Sell | Open Market | 310 | $3K | 12/20/2025 | View on chart |
| FDMT | ▲ Buy | Option Exercise | 220 | — | 12/20/2025 | View on chart |
| FDMT | ▼ Sell | Open Market | 79 | $686 | 12/20/2025 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
FDMT listed in Benzinga pre-market movers
4D Molecular Therapeutics was mentioned in a Benzinga report on stocks moving lower in Friday’s pre-market session. The article grouped FDMT with other companies like Scholastic and Zscaler, noting a generally downbeat tone among legacy education and other large-cap names. This indicates the stock was part of a broader market movement rather than reacting to a company-specific announcement.
FDMT listed in Benzinga pre-market movers. 4D Molecular Therapeutics was mentioned in a Benzinga report on stocks moving lower in Friday’s pre-market session. The article grouped FDMT with other companies like Scholastic and Zscaler, noting a generally downbeat tone among legacy education and other large-cap names. This indicates the stock was part of a broader market movement rather than reacting to a company-specific announcement.